High Performance GAP-43 Antibody to Detect Axonal Regeneration for Drug Development and Research
Inventors: Larry Benowitz
Invention Types: Research Tool, Therapeutics
Research Areas: Neurology/Neuroscience
Keywords: Antibody, Drug DiscoveryFor More Information Contact: Ives, Catherine L.
Dr. Benowitz's laboratory at Children's has made important discoveries about how to promote the rewiring of brain connections after injuries, such as stroke and spinal cord injury. In this process, his laboratory has raised an antibody against the neuron-specific phosphoprotein GAP-43. GAP43 is a crucial component of an effective regenerative response in the nervous system. It has been termed a 'growth' or 'plasticity' protein because it is expressed at high levels in neuronal growth cones during development and axonal regeneration.
This polyclonal antibody has been validated by Dr. Benowitz's and many other academic laboratories over time. This high performance antibody is now, for the first time, available for licensing.
Drug Discovery, Drug Screening and Research in:
• CNS injuries such as stroke, traumatic brain injury and spinal cord injury
• Neurodegenerative diseases, such as Alzheimer's, Parkinson's and Multiple Sclerosis
• Vision and hearing loss associated with CNS abnormalities
• Brain development
• Effect of neuro-protective agents
• Biological effects of drug addiction in the brain
• Glaucoma and blindness caused by optic nerve damage
• Gain-of-function cell therapy studies, such as the introduction of stem cells to replace neurons damaged by CNS injury
High resolution in the identification of areas of plasticity in the mature human brain. Visualization of all steps in the nervous system development cycle. Use of the antibody can also be extended to peripheral nerves with some technical guidance from Dr. Benowitzâ€™s laboratory. Most commercially available antibodies are peptide based and raised in mouse, rabbit and goat. This GAP-43 antibody is raised in sheep using the entire GAP-43 protein, what may account for its superior resolution.
• â€¢ Exclusive/non-exclusive licenses to companies developing:
o Diagnostics and/or therapies for neurological and neurodegenerative diseases and disorders
o Therapies for vision and hearing loss associated with the CNS
o Diagnosis and/or treatments for conditions related to brain development
o Diagnosis and/or treatments of drug addictions
• Non-exclusive licenses with research tools companies
• Collaborations and sponsored research
Key Publications: Shea TB, Benowitz LI. Inhibition of neurite outgrowth following intracellular delivery of anti-GAP-43 antibodies depends upon culture conditions and method of neurite induction. J Neurosci Res. 1995 Jun 15;41(3)347-54.
Shea TB, et al. Phospholipid-mediated delivery of anti-GAP-43 antibodies into neuropblastoma cells prevents neuritogenesis. J Neurosci. 1991 Jun;11(6):1685-90.
Benowitz LI, et al. Molecular properties of the growth-associated protein GAP-43 (B-50). J Neurochem. 1987 May;48(5):1640-7.
Related Publications: Kinney HC, et al. Anatomic distribution of the growth-associated protein GAP-43 in the developing human brainstem. J Neuropathol Exp Neurol. 1993 Jan;52(1):39-54.
Benowitz LI, et al. Anatomical distribution of the growth-associated protein GAP-43/B-50 in the adult rat brain. J Neurosci. 1988 Jan;8(1):339-52.
IPStatus: Not applicable